|Vanda Pharmaceuticals, Inc.|
2200 Pennsylvania Avenue NW
United States - Map
Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. The company was incorporated in 2002 and is headquartered in Washington, District of Columbia.
|Vanda Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 10; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Mihael H. Polymeropoulos M.D.,
Founder, Chief Exec. Officer, Pres and Director
|Mr. James Patrick Kelly ,
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
|Mr. Robert Repella ,
Chief Commercial Officer and Sr. VP
|Mr. Vincent J. Milano ,
Director, Chairman of Compensation Committee and Member of Audit Committee
|Mr. Gunther Birznieks ,
VP of Bus. Devel.
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|